Zenex Animal Health Acquires VievePharm for Strategic Expansion

Zenex Animal Health India Private Ltd, supported by Private Equity firm Multiples, has announced the acquisition of a majority stake in VievePharm on February 27, 2026, a Netherlands-based company specializing in natural animal nutrition. The financial terms of the deal remain undisclosed. This acquisition is expected to accelerate Zenex’s expansion into the global naturals market and establish a dedicated manufacturing and sales hub in Western Europe.

With this acquisition, Zenex aims to leverage VievePharm’s established distribution network within the European Union to enhance the export of its therapeutic and nutritional products across various formulation types. Dr. Arun Atrey, Managing Director and CEO of Zenex Animal Health, emphasized the strategic importance of this acquisition, stating, “The acquisition of VievePharm is a logical progression of our first-principles approach to animal healthcare — focusing on prevention and sustainable productivity.”

Zenex plans to integrate VievePharm’s advanced bolus technology with its own research and development capabilities, thereby offering comprehensive, science-backed solutions to address animal health challenges. Manish Gaur, a board member at Zenex and Managing Director & Head of Pharma and Healthcare at Multiples, noted that strategic acquisitions like VievePharm will play a crucial role in Zenex’s global value-creation journey.

VievePharm’s founder, Arie Boorsma, expressed enthusiasm about the partnership, stating, “Joining forces with Zenex allows us to scale our ‘Best of Nature’ philosophy to a global stage. Our commitment to sustainable livestock farming and innovation in animal nutrition aligns perfectly with Zenex’s vision.” This collaboration is expected to provide the necessary resources and reach to deepen VievePharm’s operations in the Netherlands and expand its solutions to farmers across Europe and other markets.

The acquisition comes at a time when the animal health sector is witnessing significant growth, driven by increasing demand for sustainable and natural nutrition solutions. By enhancing its market share in the European animal nutrition sector, Zenex is positioning itself to compete more effectively against other players in the industry.

Looking ahead, Zenex will focus on integrating VievePharm’s operations and aligning their processes to ensure a smooth transition. The company will also navigate regulatory compliance in the European market as it seeks to capitalize on this strategic acquisition.

In summary, this acquisition not only strengthens Zenex’s competitive position but also opens up new opportunities for growth and innovation in the animal health sector.